SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Computational Biology - The Study of Biological Systems Through Computational Techniques and Modeling - Conceptual Illustration
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy Casgevy. While Vertex handles the market, CRISPR has been focused on its clinical program.
May 7, 2025
 · 
4 min read
 · 
Annalee Armstrong
Novo Nordisk's logo on the facade of its building in Germany
Earnings
Novo Vows Smoother Market Waters for Wegovy—but Analysts Are Skeptical
The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the market position of Wegovy. But Eli Lilly’s Zepbound is quickly gaining ground, with sales just $300 million behind Wegovy in Q1.
May 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Weeks Bridge of Harvard University
Job Trends
Recent Federal Actions Put US, Massachusetts Biotech Leadership at Risk: MassBio
MassBio’s new report outlines several concerns, including NIH cuts undermining the research engine, FDA reductions delaying innovation and trade barriers disrupting supply chains.
May 7, 2025
 · 
3 min read
 · 
Angela Gabriel
3d rendering of a plastic jar with medical pills on a hand truck on blue background. Medicine and health. Bottles and containers. Healthcare industry.
Manufacturing
Amid Trump’s Trade War, Some Drugmakers Stockpile Products in U.S.
Imports of pharmaceutical products surged in March, most of which came from Ireland, historically one of the biggest exporters of medicines to the U.S.
May 7, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Trump’s US Manufacturing Push, New Vaccine Policy, Novo’s Weight Loss Pill up for FDA Review
A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will require placebo-controlled trials for all vaccine approvals; tariff threats hit BioNTech; Novo Nordisk’s FDA application for an oral version of Wegovy is accepted; and more.
May 7, 2025
 · 
1 min read
 · 
Heather McKenzie
Workplace conflict Job rivalry, jealousy among colleagues concept, angry coworker fighting by pulling golden crown metaphor of job promotion position.
Cancer
Summit’s Campaign To Conquer Keytruda Nears First Global Phase III Data
Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other branded drugmakers are also seeking to improve on the blockbuster checkpoint inhibitor.
May 7, 2025
 · 
5 min read
 · 
Nick Paul Taylor
People balance on tightly stretched ropes. Art collage.
Deals
M&A, IPOs Snarled by Policy Reality in Q1 as Pharmas Opt for Licensing Deals
M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing transactions, however, grew as pharmas looked for less-risky deals.
May 7, 2025
 · 
3 min read
 · 
Annalee Armstrong
FDA
Biotech Stocks Fall After FDA Names Vinay Prasad To Succeed Marks at CBER
The oncologist and former University of California, San Francisco, professor has long been critical of COVID-19 mandates and the accelerated approval of cancer drugs.
May 6, 2025
 · 
3 min read
 · 
Heather McKenzie
Steel Hammer,eps 8, all elemnts are in seperate layers and grouped. Please visit my portfolio for more options.
Manufacturing
Trump Orders FDA To Ease US Plant Expansion; Drops Hammer on Foreign Inspections
A new executive order from President Donald Trump aims to cut down the 5-to-10-year timeline to build new facilities while stepping up the rigor of inspections on foreign plants.
May 6, 2025
 · 
3 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS